Recently, Life Technologies Corporation (LIFE) launched the Oncomine Next Gen Sequencing Power Tools. This innovative offering from the company is an analytical tool to enable in-depth analysis of next generation sequencing (NGS) data for oncology research.
The NGS data is sourced from the data from The Cancer Genome Atlas. NGS is capable of providing insights into the factors inducing cancer. To date, over 4,500 paired tumor and samples have been analyzed.
The Oncomine NGS Power Tools is an accretive addition to Life’s Power Tools line of products. Moreover, this innovative offering from the company reflects its ability to cater to the broader needs of the cancer research space.
The Oncomine portfolio was included in the company’s profile following the takeover of Compendia Bioscience in Oct 2012. Earlier this year, in April, Life introduced its Oncomine Gene Browser and Ion Reporter Oncomine Workflow. The Oncomine Gene Browser is targeting the academic and smaller biotech market.
About Oncomine NGS Power Tools
Life’s latest portfolio addition comprises an array of software tools that will allow researchers to assess novel predicted driver mutations and gene fusions for all types of cancer. The Oncomine NGS Power Tools will allow cancer researchers access to extensive recent data.
According to the company, investigators using the NGS Power Tools identified FGFR gene fusions across different cancer types. The nine distinguished tumor types uncovered by scientists at Life are lung squamous cell cancer, bladder cancer, thyroid cancer, oral cancer, glioblastoma, and head and neck squamous cell cancer.
Following the disclosure of its acquisition by Thermo Fisher Scientific Inc. (TMO), Life sharpened focus on its product platform. We believe that the buyout will leverage Life’s attractive revenue profile. The acquisition is expected to close in early 2014.
Given Life’s expansive line of consumables for genomic, and molecular and cell biology, the takeover will complement Thermo Fisher’s market-leading portfolio of analytical technologies and specialty diagnostics.
However, with the current stock price reflecting the potential upsides, Life carries a Zacks Rank #4 (Sell). While the upsides are already built into Life’s shares, we are more positive about other medical stocks such as Haemonetics Corporation (HAE) and Myriad Genetics Inc. (MYGN). These stocks carry a favorable Zacks Rank #1 (Strong Buy).
More From Zacks.com